Last reviewed · How we verify
immediate release guanfacine hydrochloride
At a glance
| Generic name | immediate release guanfacine hydrochloride |
|---|---|
| Also known as | Tenex |
| Sponsor | Shire |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ACE-D Aim 3 Clinical Cognitive Trial to Enhance Translation in Depression (PHASE2)
- Guanfacine for Hyperactivity in Children With Down Syndrome (HYPEbeGONE_DS) (PHASE2)
- Treating Young Children With Attention Deficit Hyperactivity Disorder (PHASE4)
- The Effect of Guanfacine on Delirium in Critically Ill Patients (PHASE3)
- The BIomarker Guided (BIG) Study for Depression (PHASE4)
- Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome (PHASE4)
- Guanfacine Immediate-release Electrocardiogram Results (QTc) Study (PHASE1)
- Guanfacine Extended Release and Mindfulness Skills Therapy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- immediate release guanfacine hydrochloride CI brief — competitive landscape report
- immediate release guanfacine hydrochloride updates RSS · CI watch RSS
- Shire portfolio CI